| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 26
| Issue : 1 | Page : 103 |
|
|
Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19
Maryam Mobini1, Roya Ghasemian2, Laleh Vahedi Larijani3, Maede Mataji4, Iradj Maleki5
1 Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2 Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran
3 Immunogenetic Research Center, Mazandaran University of Medical Sciences, Sari, Iran
4 Department of Internal Medicine, Mazandaran University of Medical Sciences, Sari, Iran
5 Gut and Liver Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
Correspondence Address:
Dr. Iradj Maleki
Endoscopy Unit, Imam Khomeini Hospital, Amir Mazandarani Street, Sari
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jrms.JRMS_923_20
|
|
|
Background: The cause of coronavirus disease 2019 (COVID-19) is a virus which can lead to severe acute respiratory syndrome-CoV-2 (SARS-COV-2). There are evidences of involvement of immune system in pathogenesis of this disease. We investigated the presence of various vasculitis-associated autoantibodies and complement levels in patients with COVID-19. Materials and Methods: Patients with severe or critical type of COVID-19 were evaluated for symptoms, signs, and laboratory tests of vasculitis syndromes including rheumatoid factor (RF), antinuclear antibody (ANA), anti-double-stranded DNA, c and p anti-neutrophilic cytoplasmic antibody (c ANCA and P ANCA), and complement levels. Results: The study was performed in forty patients with severe or critical illness. The mean age of the participants was 48.5 ± 9.8 years. All patients had pulmonary involvement in lung computed tomography scans. Vasculitis laboratory test results included RF in two patients, ANA in three patients, and ANCA in one patient. Seventeen (42.5%) patients had hypocomplementemia in one or more complement tests. Four patients expired, of whom three had a decrease in complement level. Conclusion: Decrease in complement levels may predict a critical state of COVID-19 disease. Therefore, measuring its levels may be of great benefit in making earlier decisions to initiate disease-suppressing treatments including corticosteroids.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
